AstraZeneca is likely to conduct an additional global trial to assess the efficacy of its Covid-19 vaccine, Bloomberg reported. According to the company's chief executive officer, the new trial would be run instead of adding an arm to an ongoing US trial and would evaluate a lower dosage that performed better than a full amount in Astra's studies.